Recombinant Human Oncostatin M/OSM stimulates proliferation in the TF‑1 human erythroleukemic cell line (orange line), as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human Oncostatin ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.5 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for gp130/CD130 Antibody (28126) [Unconjugated]
gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form
IL-6 receptor subunit beta
IL-6R subunit beta
interleukin 6 signal transducer (gp130, oncostatin M receptor)
interleukin receptor beta chain
interleukin-6 receptor subunit beta
Interleukin-6 signal transducer
Membrane glycoprotein 130
membrane glycoprotein gp130
Oncostatin-M receptor subunit alpha
130 (gp130; also known as IL-6 signal transducer, IL-6 receptor beta,
oncostatin-M alpha subunit) is a ubiquitously expressed, 130 kDa type I
transmembrane glycoprotein and member of the type II subfamily, type I
cytokine receptor family. Functionally, it is responsible for
transduction of the IL-6 signal across the plasma membrane (1). Rat
gp130 is synthesized as a 918 amino acid (aa) precursor with a 22 aa
signal sequence, a 596 aa extracellular domain (ECD), a 22 aa
transmembrane region, and a 278 aa cytoplasmic tail. Eleven potential
N-linked glycosylation sites are found within the rat gp130 ECD (1). The
ECD also contains an N terminal immunoglobulin (Ig)-like C2-type
domain, followed by the cytokine receptor homology region (CHR) which is
made up of two fibronectin type III-like domains and a WSXWS motif, and
three additional fibronectin type III-like domains (2). The domains in
the CHR are the structural hallmarks of the hematopoietic cytokine
receptor family (2). Human gp130 shares 73% and 79% aa sequence identity
with mouse and rat gp130, respectively. Gp130 serves as the signal
transducing receptor subunit for the IL-6-type cytokines consisting of
interleukin (IL)-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M
(OSM), ciliary neurotrophic factor (CNTF), new neurotrophin factor-1
(NNT-1), IL-27, cardiotrophin-1 (CT-1), and cardiotrophin like cytokine
(CLC) (2 - 5). These cytokines are involved in a variety of functions
including the modulation of inflammatory and immune responses, heart
development, fertility, and many other activities (2).
Wang, Y. et al. (1992) Genomics 14:666.
Muller-Newen, G. (2003) Sci. STKE pe40.
Heinrich, P.C. et al. (2003) Biochem. J. 374:1.
Stuhlmann-Laeisz, C. et al. (2006) Mol. Biol. Cell 17:2986.
Fischer, P. and D. Hilfiker-Kleiner (2008) Br. J. Pharmacol. 153:S414.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our gp130/CD130 Antibody (28126) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.